Left Ventricular Mass
Left ventricular mass (LVM) refers to the total weight of the muscular wall of the heart’s left ventricle, which is the primary pumping chamber responsible for circulating oxygenated blood throughout the body.[1]. It serves as a vital indicator of overall cardiac health and function.
An increase in left ventricular mass is often a compensatory response by the heart to pathological stimuli, such as high blood pressure (hypertension), obesity, or injury to the heart muscle. This increase initially helps maintain the heart’s pumping capacity (cardiac output) under stress.[1]. However, sustained or excessive increases in LVM can become detrimental, leading to adverse health outcomes.
Left ventricular mass is a sensitive predictor of future cardiovascular mortality and morbidity across all ages, genders, and populations.[1]. Abnormally high LVM is a key characteristic of left ventricular hypertrophy (LVH), a condition defined by specific thresholds, such as a left ventricular mass index (LVMI) greater than 47 g/m2.7 in women and greater than 50 g/m2.7 in men.[1].
Studies indicate that LVM is a complex trait, meaning its variation is influenced by multiple genetic and environmental factors. [1]. Heritability estimates, which quantify the proportion of variation in a trait attributable to genetic differences, typically range between 17% and 59%. [1]. Research has identified specific genetic variants associated with LVM, including a single-nucleotide polymorphism (SNP) in the KCNB1 gene [1], and genetic variation in NCAM1 contributing to left ventricular wall thickness in hypertensive families [2]. Earlier studies also investigated associations with genes such as angiotensin-converting enzyme (ACE), guanine nucleotide-binding protein (GNB3), insulin-like growth factor (IGF-1), and neuropeptide Y (NPY), though findings for some of these genes have been inconsistent. [1].
The assessment of left ventricular mass typically involves non-invasive methods like echocardiography. Measurements are made using M-mode or 2D imaging, and LVM is calculated from end-diastolic dimensions using anatomically validated formulas, often indexed to height to standardize for body size.[1]. Given its strong predictive power for cardiovascular disease, understanding the genetic and environmental factors that influence left ventricular mass is fundamental for public health. This knowledge helps in developing strategies for early risk assessment, prevention, and targeted treatments for heart conditions.
Limitations
Section titled “Limitations”Understanding the genetic and environmental factors contributing to left ventricular mass (LVM) is crucial for cardiovascular health, yet several limitations inherent in current research methodologies and study designs necessitate careful interpretation of findings. These limitations include challenges in study design and statistical power, issues of generalizability across diverse populations, and the complex interplay of genetic and environmental factors that remain incompletely understood.
Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”Genetic association studies for left ventricular mass face challenges related to the scope and depth of genomic coverage and the statistical rigor of findings. Early genome-wide association studies (GWAS), for instance, utilized platforms like the Affymetrix GeneChip Human Mapping 100k Set, which provided relatively limited whole-genome coverage, potentially missing significant genetic variants due to sparse marker density[1]. Furthermore, while GWAS-validation study designs are crucial for confirming initial findings, a notable proportion of initial associations may prove to be false positives; one study observed that nearly half of the identified single-nucleotide polymorphisms (SNPs) were not replicated in validation cohorts, highlighting the need for robust replication across independent populations [1].
Beyond genotyping, consistent and precise phenotyping of left ventricular mass itself presents difficulties. Averaging echocardiographic measurements across multiple examinations spanning extended periods, such as twenty years, can introduce misclassification due to evolving echocardiographic equipment and methodologies[3]. Such averaging also assumes that the same genetic and environmental influences operate consistently across a wide age range, potentially masking age-dependent gene effects that might be overlooked when observations are pooled over decades [3]. Additionally, analyses often assume an additive genetic model, which may not fully capture more complex genetic architectures or interactions [4].
Generalizability and Population Specificity
Section titled “Generalizability and Population Specificity”A significant limitation in understanding the genetics of left ventricular mass is the restricted generalizability of findings, primarily due to cohort biases toward specific ancestral groups. Many studies have predominantly included participants of white European descent, making it difficult to extrapolate the identified genetic associations and their effect sizes to other ethnic populations[3]. This lack of diversity means that the genetic architecture influencing LVM in populations such as African Americans, Hispanic individuals, or isolated founder populations remains less comprehensively studied, potentially leading to an incomplete global understanding of LVM genetics [5].
The genetic landscape and environmental exposures can vary significantly between populations, implying that genetic variants associated with LVM in one group may not hold the same relevance or effect size in another. Differences in allele frequencies, linkage disequilibrium patterns, and the prevalence of environmental risk factors across diverse ancestries can lead to population-specific genetic associations. Therefore, findings from one cohort may not be directly transferable, necessitating dedicated research in a broader range of ancestral groups to ensure equitable clinical translation and risk prediction.
Complex Genetic Architecture and Environmental Interactions
Section titled “Complex Genetic Architecture and Environmental Interactions”Left ventricular mass is a complex, multifactorial trait influenced by a combination of genetic predispositions and environmental factors, creating challenges in fully elucidating its etiology. While studies have demonstrated both genetic and environmental contributions to LVM, the intricate interplay between these factors, including specific gene-environment interactions, is not yet fully understood[6]. Environmental confounders, such as hypertension, diabetes, and lifestyle factors, are known to significantly impact LVM and can modify the expression of genetic risk factors, making it difficult to isolate the precise genetic effects[1].
The current understanding of LVM genetics also faces remaining knowledge gaps, particularly concerning the “missing heritability”—the portion of heritable variation that cannot be explained by currently identified genetic variants. This suggests that many genetic influences may involve rare variants, complex polygenic interactions, or epigenetic mechanisms that are not adequately captured by current GWAS methodologies focusing on common variants. A complete picture requires further research into these complex interactions and the comprehensive mapping of all contributing genetic and environmental factors across the lifespan.
Variants
Section titled “Variants”Genetic variations play a crucial role in influencing complex traits such as left ventricular mass (LVM), a key indicator of heart health. The left ventricle is the main pumping chamber of the heart, and its size and structure are subject to both genetic and environmental factors. Elevated LVM can indicate left ventricular hypertrophy (LVH), a condition associated with increased risk of cardiovascular events. Genome-wide association studies (GWAS) have identified numerous genetic loci that contribute to the heritability of LVM and related echocardiographic dimensions[7]. These studies highlight how subtle changes in DNA, known as single nucleotide polymorphisms (SNPs), can influence the intricate processes governing cardiac structure and function [8].
The TTN gene encodes Titin, a massive protein essential for the elasticity and structural integrity of muscle, particularly in the heart. Variants in TTN are well-established causes of various cardiomyopathies, including dilated and hypertrophic forms, which directly impact left ventricular size and function. The variants rs2255167 and rs2562845 within or near TTN, along with rs6755784 in its antisense RNA TTN-AS1, may influence cardiac remodeling pathways. Antisense RNAs like TTN-AS1 can regulate the expression of their corresponding protein-coding genes, suggesting that these variants could alter Titin’s production or function, thereby affecting the heart’s ability to maintain normal LVM. Similarly, the ADAMTS10 gene, coding for a metalloproteinase involved in extracellular matrix organization, harbors variant rs62621197 . Given its role in tissue remodeling, changes in ADAMTS10 activity could contribute to alterations in the cardiac extracellular matrix, potentially influencing LVM and overall cardiac architecture.
Other variants, such as rs1421085 in the FTOgene, are primarily known for their strong association with obesity-related traits like body mass index (BMI)[9]. Since obesity is a significant risk factor for increased LVM and left ventricular hypertrophy, variants inFTO that predispose individuals to higher BMI could indirectly contribute to greater LVM [10]. The HMGA2 gene, represented by rs10878349 , is involved in cell proliferation and differentiation, often linked to human height and body size. Variations in HMGA2 could influence overall somatic growth, which in turn might correlate with heart size and LVM. Furthermore, non-coding RNAs like MIR588, regulated by rs9388498 within the MIR588 - RNU6-200Plocus, play vital roles in gene expression regulation, and their dysregulation can impact various biological processes, including cardiac development and disease. Thers6503451 variant in MAPT-AS1, an antisense RNA to the MAPT (Tau) gene, could also indirectly affect cellular pathways relevant to cardiac health.
Finally, variants like rs143741275 in the ZNF619P1 - HMGN1P19 region and rs2732685 in MAPK8IP1P1 - ARL17B involve pseudogenes, which, despite not coding for functional proteins themselves, can influence the expression of their functional counterparts or other nearby genes through various regulatory mechanisms. The variant rs4985155 in PDXDC1(Pyridoxal-dependent decarboxylase homolog 1) is less characterized in cardiac context, but its involvement in metabolic pathways could have downstream effects on cardiac metabolism and energy utilization, thereby contributing to LVM variations. Collectively, these diverse genetic variants underscore the complex polygenic nature of LVM, where both direct cardiac structural genes and genes influencing systemic factors like metabolism and body composition contribute to individual differences in heart size and health[1].
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs2255167 rs2562845 | TTN-AS1, TTN | left ventricular mass left ventricular mass index |
| rs62621197 | ADAMTS10 | body height BMI-adjusted waist-hip ratio BMI-adjusted waist circumference appendicular lean mass health trait |
| rs6755784 | TTN-AS1 | left ventricular systolic function measurement heart function attribute left ventricular mass left ventricular diastolic function measurement left ventricular ejection fraction measurement |
| rs9388498 | MIR588 - RNU6-200P | kidney volume BMI-adjusted waist-hip ratio total cholesterol measurement low density lipoprotein cholesterol measurement left ventricular mass index |
| rs1421085 | FTO | body mass index obesity energy intake pulse pressure measurement lean body mass |
| rs6503451 | MAPT-AS1 | left ventricular mass index left ventricular mass |
| rs10878349 | HMGA2 | cerebral cortex area attribute systolic blood pressure left ventricular mass anthropometric measurement fat pad mass |
| rs143741275 | ZNF619P1 - HMGN1P19 | appendicular lean mass Abnormality of the skeletal system left ventricular systolic function measurement left ventricular mass left ventricular ejection fraction measurement |
| rs2732685 | MAPK8IP1P1 - ARL17B | fatty acid amount omega-3 polyunsaturated fatty acid measurement left ventricular mass left ventricular function left ventricular structural measurement |
| rs4985155 | PDXDC1 | femoral neck bone mineral density body mass index omega-6 polyunsaturated fatty acid measurement hip circumference triglyceride measurement, body mass index |
Defining Left Ventricular Mass and its Measurement
Section titled “Defining Left Ventricular Mass and its Measurement”Left ventricular mass (LVM) refers to the total muscle tissue weight of the heart’s main pumping chamber, the left ventricle. It is a critical anatomical trait reflecting the heart’s workload and adaptation. LVM is precisely measured using echocardiography, specifically M-mode or two-dimensional (2D) echocardiography, following recommendations from professional bodies such as the American Society of Echocardiography[11]. The mass is typically calculated from end-diastolic dimensions using anatomically validated formulas [1]. To standardize LVM across individuals of different body sizes, it is often indexed to height to the power of 2.7 (height^2.7), resulting in the Left Ventricular Mass Index (LVMI), which serves as an operational definition[1]. The reproducibility of these echocardiographic measures is regularly assessed in substudies to ensure measurement consistency [1].
Classification and Clinical Significance of Left Ventricular Hypertrophy
Section titled “Classification and Clinical Significance of Left Ventricular Hypertrophy”An increase in left ventricular mass beyond normal limits is classified as Left Ventricular Hypertrophy (LVH), a significant clinical condition. This classification is based on specific diagnostic criteria involving thresholds of the Left Ventricular Mass Index (LVMI)[1]. For instance, LVH is commonly defined as an LVMI greater than 47 g/m^2.7 in women and greater than 50 g/m^2.7 in men [1]. Such conditions include stroke, congestive heart failure, and overall cardiovascular mortality, with LVH having a notable impact on survival[12].
Causes of Left Ventricular Mass
Section titled “Causes of Left Ventricular Mass”Left ventricular mass is a complex trait influenced by a combination of genetic, environmental, and physiological factors. Increased left ventricular mass is a sensitive predictor of cardiovascular mortality and morbidity across various demographics . This adaptive growth aims to maintain adequate cardiac output despite increased workload. However, while initially beneficial, an elevated LVM is a sensitive and robust predictor of cardiovascular mortality and morbidity across diverse populations, including all genders, races, and ages[1]. The clinical condition of excessive LVM is termed left ventricular hypertrophy (LVH), which is specifically defined by a left ventricular mass index (LVMI) exceeding 47 g/m2.7 in women and 50 g/m2.7 in men[1].
Genetic Architecture of Left Ventricular Mass
Section titled “Genetic Architecture of Left Ventricular Mass”Left ventricular mass is recognized as a complex trait, influenced by a combination of genetic and environmental factors. Genetic control is a significant determinant of LVM, with heritability estimates typically ranging between 0.17 and 0.59[1]. Early genetic studies identified associations between LVM and specific genes, including the angiotensin-converting enzyme (ACE) gene, the guanine nucleotide-binding protein beta-3 subunit (GNB3) gene, the insulin-like growth factor 1 (IGF-1) gene, and the neuropeptide Y (NPY) gene[1]. However, the consistency of these associations has varied, with some studies failing to replicate findings for genes like ACE and GNB3 [1]. More recent genome-wide association studies (GWAS) have expanded this understanding, identifying novel genetic loci such as a single-nucleotide polymorphism (SNP) in the KCNB1 gene associated with LVM, and genetic variations in NCAM1that contribute to left ventricular wall thickness, particularly in individuals with a family history of hypertension[1]. These findings underscore the intricate polygenic nature of LVM and the potential for context-dependent genetic effects, especially in the presence of hypertension[13].
Molecular and Cellular Pathways in Ventricular Remodeling
Section titled “Molecular and Cellular Pathways in Ventricular Remodeling”The process of ventricular remodeling, which underlies changes in LVM, involves a sophisticated network of molecular and cellular pathways regulated by various key biomolecules. The angiotensin-converting enzyme (ACE), encoded by the ACE gene, is a central enzyme within the renin-angiotensin-aldosterone system (RAAS), a critical hormonal system that regulates blood pressure and fluid balance, and significantly influences cardiac growth and remodeling [1]. Angiotensin II, a potent peptide produced by the RAAS, is known to antagonize cyclic guanosine monophosphate (cGMP) signaling in vascular smooth muscle cells, a mechanism that impacts vascular tone and myocardial workload [8]. Other important biomolecules include insulin-like growth factor 1 (IGF-1), a hormone that promotes cellular growth and metabolism, contributing to the hypertrophic response of myocardial cells[1]. Additionally, genes such as KCNB1, which codes for a voltage-gated potassium channel subunit, and NCAM1, a cell adhesion molecule, are implicated in LVM regulation, suggesting roles in ion channel function, cell-to-cell communication, and the structural integrity of the ventricular myocardium [1].
Systemic Influences and Clinical Consequences
Section titled “Systemic Influences and Clinical Consequences”Left ventricular mass is profoundly influenced by systemic physiological conditions and, in turn, exerts significant systemic consequences on cardiovascular health. Chronic pathological stimuli, including sustained hypertension, obesity, and prior myocardial injury, are primary drivers of increased LVM[1]. These conditions impose heightened demands or stress on the heart, triggering the compensatory increase in myocardial tissue. At the organ level, excessive LVM can lead to adverse structural and functional alterations, such as left ventricular dilatation, which substantially increases the risk of developing congestive heart failure[8]. The integrity of left ventricular systolic function, often compromised by these structural changes, is a critical determinant of outcomes for individuals with congestive heart failure, particularly among the elderly[14]. Echocardiography serves as a crucial non-invasive imaging modality for assessing these cardiac structural and functional dimensions, enabling the precise calculation of LVM using anatomically validated formulas and its indexing to body surface area for clinical evaluation[1].
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Genetic Predisposition and Regulatory Mechanisms
Section titled “Genetic Predisposition and Regulatory Mechanisms”Heritability of left ventricular mass (LVM) has been consistently observed in various populations, including the Framingham Heart Study, the Tecumseh Offspring Study, and studies of Black twins, indicating a significant genetic contribution to this cardiac trait.[7] Genetic variation plays a crucial role in determining LVM, with studies identifying specific single-nucleotide polymorphisms (SNPs) associated with its variability. For instance, genetic variation in NCAM1 has been found to contribute to left ventricular wall thickness in hypertensive families, suggesting a role for this gene in cardiac structural adaptation. [2]
Another identified locus is a SNP in KCNB1, which has been associated with LVM in humans within the HyperGEN Study. [15] These genetic influences highlight the importance of gene regulation in controlling cardiac growth and remodeling. Such variations can impact the expression or function of proteins involved in myocardial development or response to stress, thereby influencing the overall cardiac architecture and its susceptibility to hypertrophy.
Signaling Pathways in Cardiac Adaptation
Section titled “Signaling Pathways in Cardiac Adaptation”The regulation of left ventricular mass involves complex intracellular signaling cascades that respond to various physiological stimuli. A key example includes the interaction between angiotensin II and cGMP signaling, as research indicates that angiotensin II can antagonize cGMP signaling in vascular smooth muscle cells.[3] This interaction suggests a broader role for these pathways in cardiovascular remodeling, potentially affecting cardiomyocyte growth and extracellular matrix deposition, which are fundamental to changes in LVM.
Such signaling events typically involve receptor activation at the cell surface, leading to a cascade of phosphorylation events that ultimately regulate the activity of transcription factors. These transcription factors then control the expression of genes involved in cellular growth, protein synthesis, and energy metabolism, thereby orchestrating the adaptive or maladaptive remodeling of the left ventricle. Understanding these intricate feedback loops is essential for deciphering the molecular basis of LVM regulation.
Metabolic Interplay and Cardiac Growth
Section titled “Metabolic Interplay and Cardiac Growth”Changes in left ventricular mass are intimately linked with metabolic pathways, particularly those governing energy metabolism and biosynthesis within cardiomyocytes. Cardiac hypertrophy, an increase in LVM, is an energy-intensive process requiring a substantial increase in ATP production and macromolecular synthesis. This demand necessitates a finely tuned metabolic regulation, impacting fuel substrate utilization and overall metabolic flux control to support increased protein synthesis and cellular growth.
Systemic metabolic conditions, such as obesity, are strongly associated with altered left ventricular mass, emphasizing the systemic-level integration of metabolic and cardiac health. Genome-wide association studies have identified numerous genetic loci associated with body mass index (BMI) and other anthropometric traits.[16]These genetic predispositions to obesity can indirectly influence LVM by altering metabolic load and hormonal signaling that impacts cardiac muscle.
Systems-Level Integration and Disease Dynamics
Section titled “Systems-Level Integration and Disease Dynamics”The development and regulation of left ventricular mass are not isolated cellular events but rather emergent properties resulting from the intricate crosstalk between multiple signaling pathways and network interactions within the cardiovascular system. Hypertension, a major risk factor for increased LVM, exemplifies this hierarchical regulation, where sustained elevated blood pressure leads to increased cardiac workload.[2] The heart responds through compensatory mechanisms, initially by increasing muscle mass to maintain pumping efficiency, a process that, if prolonged, can transition into maladaptive remodeling.
Dysregulation within these integrated pathways, whether genetic or environmentally induced, contributes to pathological increases in LVM. For example, the context-dependent genetic effects in hypertension highlight how genetic predispositions interact with environmental factors to influence cardiac structure.[13] Identifying these dysregulated pathways and their components, such as specific ion channels like KCNB1, offers potential therapeutic targets for mitigating adverse cardiac remodeling and its associated cardiovascular risks. [15]
Clinical Relevance
Section titled “Clinical Relevance”Prognostic Value and Cardiovascular Risk Stratification
Section titled “Prognostic Value and Cardiovascular Risk Stratification”Left ventricular mass (LVM) is a critical prognostic indicator for cardiovascular health, predicting future morbidity and mortality across diverse populations, including all genders, races, and age groups[1]. Elevated LVM, particularly in the form of left ventricular hypertrophy (LVH), is strongly associated with adverse outcomes such as coronary heart disease, stroke, and congestive heart failure[17]. Studies have consistently highlighted its predictive power for cardiovascular events and mortality, even in individuals with preserved left ventricular ejection fraction[18].
This robust prognostic capability allows LVM to be used in risk stratification, helping clinicians identify individuals at high risk for cardiovascular events. By quantifying LVM, healthcare providers can better assess individual patient risk profiles, which is crucial for guiding personalized prevention strategies and early interventions [17], [18]. The recognition of LVH, defined as an indexed LVM exceeding 47 g/m^2.7 in women and 50 g/m^2.7 in men, facilitates targeted management to mitigate long-term cardiovascular complications [1].
Clinical Applications in Diagnosis and Monitoring
Section titled “Clinical Applications in Diagnosis and Monitoring”The assessment of LVM is a fundamental clinical application, primarily utilizing echocardiography to evaluate cardiac structure and function [1]. Echocardiographic techniques, including M-mode or 2D echocardiography, allow for precise calculation of LV mass using anatomically validated formulas, typically indexed to height^2.7 to account for body size [1]. This diagnostic utility extends to identifying the presence of left ventricular hypertrophy, a significant marker of cardiac remodeling in response to various pathological stimuli.
Beyond initial diagnosis, LVM serves as a vital parameter for monitoring disease progression and evaluating the effectiveness of therapeutic interventions. Changes in LVM over time can reflect the impact of treatments for conditions like hypertension or heart failure, providing objective evidence of cardiac response[14]. Regular assessment of LVM can inform adjustments to treatment regimens, helping optimize patient care and potentially prevent the development of more severe cardiac complications, such as left ventricular dilation and subsequent congestive heart failure[8].
Genetic and Environmental Determinants of LVM
Section titled “Genetic and Environmental Determinants of LVM”Left ventricular mass is a complex trait influenced by both genetic predisposition and environmental factors, with heritability estimates ranging from 0.17 to 0.59 across various populations[1], [19], [7], [20], [21]. Pathological stimuli such as hypertension, obesity, and myocardial injury are recognized environmental contributors that can lead to increased LVM[1]. Understanding these complex interactions is crucial for a comprehensive approach to patient care.
Research has identified specific genetic loci and genes associated with LVM, including polymorphisms in KCNB1, NCAM1, ACE, GNB3, IGF-1, and NPY [1], [22]. While some genetic associations have been replicated, others show variability across studies, highlighting the polygenic nature of LVM. This genetic understanding holds promise for personalized medicine, where genetic profiles could one day inform individual risk assessments and tailor prevention or treatment strategies for LVM-related cardiovascular conditions, especially in individuals with a family history or specific comorbidities.
Frequently Asked Questions About Left Ventricular Mass
Section titled “Frequently Asked Questions About Left Ventricular Mass”These questions address the most important and specific aspects of left ventricular mass based on current genetic research.
1. My dad has a thick heart; am I likely to get one?
Section titled “1. My dad has a thick heart; am I likely to get one?”Yes, there’s definitely a genetic component. Studies show that between 17% and 59% of the variation in left ventricular mass is due to inherited differences. Specific genes likeKCNB1 and NCAM1 have been linked to heart wall thickness, so a family history does increase your personal risk.
2. Can my healthy habits really overcome my family’s heart history?
Section titled “2. Can my healthy habits really overcome my family’s heart history?”Absolutely! While genetics play a significant role in your risk for increased left ventricular mass, environmental factors and lifestyle choices are crucial. Managing things like your blood pressure, weight, and general health can significantly modify how your genetic predispositions express themselves, helping to protect your heart.
3. Does my weight actually affect how thick my heart muscle is?
Section titled “3. Does my weight actually affect how thick my heart muscle is?”Yes, it does. Obesity is a major “pathological stimulus” that can cause your left ventricular mass to increase. When you carry excess weight, your heart has to work harder to pump blood throughout your body, leading to a compensatory thickening of the muscle over time.
4. Does my background affect my risk for a thick heart?
Section titled “4. Does my background affect my risk for a thick heart?”Yes, your ethnic or ancestral background can play a role. Many studies have primarily focused on people of white European descent, and the genetic risk factors and their impact can vary in other populations, such as African Americans or Hispanic individuals, due to differences in genetic makeup and environmental exposures.
5. If I have high blood pressure, does my heart muscle get thicker?
Section titled “5. If I have high blood pressure, does my heart muscle get thicker?”Yes, high blood pressure (hypertension) is one of the primary reasons your heart’s left ventricle might become thicker. Your heart has to exert more force to pump blood against the increased resistance in your arteries, causing the muscle to grow larger and heavier over time.
6. Can I make my heart muscle healthier by changing my lifestyle?
Section titled “6. Can I make my heart muscle healthier by changing my lifestyle?”Yes, you can. Since an increase in left ventricular mass is often a response to conditions like high blood pressure and obesity, adopting a healthier lifestyle can reduce the strain on your heart. This can help prevent further thickening and, in some cases, even lead to a reduction in heart muscle mass, improving your overall heart health.
7. Can doctors tell if my heart muscle is getting too thick early?
Section titled “7. Can doctors tell if my heart muscle is getting too thick early?”Yes, they can. Doctors typically assess left ventricular mass using non-invasive imaging like echocardiography. This measurement is considered a sensitive predictor of future cardiovascular problems, so it can provide an early warning sign if your heart muscle is becoming abnormally thick.
8. Why do some healthy people still get a thick heart muscle?
Section titled “8. Why do some healthy people still get a thick heart muscle?”It’s complex because left ventricular mass is influenced by many factors beyond just lifestyle. While some specific genes likeKCNB1 and NCAM1 are known to contribute, there’s also “missing heritability,” meaning many other genetic influences, potentially rare variants or complex interactions, are not yet fully understood.
9. My sibling’s heart is fine, but mine is thicker. Why?
Section titled “9. My sibling’s heart is fine, but mine is thicker. Why?”Even within families, individual differences are common. While left ventricular mass has a significant genetic component, your unique combination of inherited genetic variants and distinct environmental exposures – like specific dietary habits, stress levels, or other lifestyle factors – can lead to different outcomes compared to your sibling.
10. Why do some heart studies seem to contradict each other?
Section titled “10. Why do some heart studies seem to contradict each other?”Research on complex traits like left ventricular mass can be challenging. Early genetic studies sometimes had limited coverage of the genome or struggled to consistently replicate findings across different populations, leading to inconsistent results for certain genes. It highlights the intricate nature of these conditions and the need for ongoing, robust research.
This FAQ was automatically generated based on current genetic research and may be updated as new information becomes available.
Disclaimer: This information is for educational purposes only and should not be used as a substitute for professional medical advice. Always consult with a healthcare provider for personalized medical guidance.
References
Section titled “References”[1] Arnett, D. K. “Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study.”BMC Medical Genetics, vol. 10, 2009, p. 43.
[2] Arnett, D. K., et al. “Genetic variation in NCAM1 contributes to left ventricular wall thickness in hypertensive families.” Circulation Research, 17 Apr. 2012.
[3] Vasan, R. S. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, suppl. 1, 2007.
[4] Berndt, S. I., et al. “Genome-wide meta-analysis identifies 11 new loci for anthropometric traits and provides insights into genetic architecture.” Nature Genetics, 2013.
[5] Lowe, Jennifer K. et al. “Genome-wide association studies in an isolated founder population from the Pacific Island of Kosrae.” PLoS Genetics, vol. 5, no. 2, 2009, e1000365.
[6] Harshfield, G. A., Grim, C. E., Hwang, C., Savage, D. D., Anderson, S. J. “Genetic and environmental influences on echocardiographically determined left ventricular mass in black twins.”American Journal of Hypertension, vol. 3, 1990, pp. 538-543.
[7] Post, W. S., et al. “Heritability of Left Ventricular Mass : The Framingham Heart Study.”Hypertension, 1997.
[8] Vasan, RS, Larson MG, Benjamin EJ, Evans JC, Levy D. “Left ventricular dilatation and the risk of congestive heart failure in people without myocardial infarction.”
[9] Scuteri, Angelo et al. “Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits.”PLoS Genet, vol. 3, no. 7, 2007, e115.
[10] Manning, Alisa K. et al. “A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance.”Nat Genet, vol. 44, no. 6, 2012, pp. 659-669.
[11] Devereux, Richard B., et al. “Standardization of M-mode echocardiographic left ventricular anatomic measurements.” Journal of the American College of Cardiology, vol. 4, no. 6, 1984, pp. 1222-1230.
[12] Casale, Patricia N., et al. “Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men.”Journal of the American College of Cardiology, vol. 7, no. 4, 1986, pp. 764-771.
[13] Kardia, S. L. “Context-dependent genetic effects in hypertension.”Current Hypertension Reports, vol. 2, 2000, pp. 32-38.
[14] Gottdiener, J. S., McClelland, R. L., Marshall, R., Shemanski, L., Furberg, C. D., Kitzman, D. W., Cushman, M., Polak, J., Gardin, J. M., Gersh, B. J., Aurigemma, G. P., Manolio, T. A. “Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study.”Annals of Internal Medicine, vol. 137, 2002, pp. 631-639.
[15] Arnett, Donna K. “Genome-wide association study identifies single-nucleotide polymorphism in KCNB1 associated with left ventricular mass in humans: the HyperGEN Study.”BMC Med Genet, 2007.
[16] Comuzzie, Anthony G. et al. “Novel genetic loci identified for the pathophysiology of childhood obesity in the Hispanic population.”PLoS One, vol. 7, no. 12, 2012, e51954.
[17] Gardin, JM, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. “M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study).”Am J Cardiol, 2001.
[18] Milani, RV, Lavie CJ, Mehra MR, Ventura HO, Kurtz JD, Messerli FH. “Left ventricular geometry and survival in patients with normal left ventricular ejection fraction.” Am J Cardiol, 2006.
[19] Sharma, P, Middelberg RP, Andrew T, Johnson MR, Christley H, Brown MJ. “Heritability of left ventricular mass in a large cohort of twins.”J Hypertens, 2006.
[20] Chien, K. L., Hsu, H. C., Su, T. C., Chen, M. F., Lee, Y. T. “Heritability and major gene effects on left ventricular mass in the Chinese population: a family study.”BMC Cardiovascular Disorders, vol. 6, 2006, p. 37.
[21] Palatini, P, Krause L, Amerena J, Nesbitt S, Majahalme S, Tikhonoff V, Valentini M, Julius S. “Genetic contribution to the variance in left ventricular mass: the Tecumseh Offspring Study.”J Hypertens, 2001.
[22] Arnett, DK, et al. “Genetic variation in NCAM1 contributes to left ventricular wall thickness in hypertensive families.” Circ Res, 2011.